Pharmaceutical composition for preventing or treating neurodegenerative diseases comprising graphene quantum dots as active ingredient

Graphene quantum dots address the inadequacies in treating neurodegenerative diseases by inhibiting stress granule and protein aggregate formation, effectively delaying disease onset and improving muscle strength in TDP-43 protein-based conditions like ALS and FTD.

WO2024248251A1PCT designated stage expired Publication Date: 2024-12-05GRAPHENE SQUARE CHEM INC +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
PCT/KR2023/019959
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-11-20
Filing Date
2023-12-06
Publication Date
2024-12-05

AI Technical Summary

Technical Problem

Current treatments for neurodegenerative diseases, particularly those related to TDP-43 protein-based conditions like amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), are inadequate in preventing or treating the diseases effectively, as they fail to control the formation of stress granules and protein aggregates that are central to the pathogenesis.

Method used

The use of graphene quantum dots, with average diameters ranging from 1 to 100 nm, which inhibit the formation of stress granules and protein aggregates, including TDP-43 and FUS protein aggregates, thereby delaying disease onset, extending lifespan, improving muscle strength, and reducing nerve damage caused by immune responses.

Benefits of technology

Graphene quantum dots effectively delay disease onset, extend lifespan, improve muscle strength, and prevent continuous nerve damage by controlling the formation of stress granules and protein aggregates, offering a potential treatment for TDP-43 protein-based diseases such as ALS and FTD.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure KR2023019959_05122024_PF_FP_ABST
    Figure KR2023019959_05122024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a pharmaceutical composition comprising graphene quantum dots as an active ingredient for preventing or treating neurodegenerative diseases and, more specifically, to a pharmaceutical composition comprising graphene quantum dots to inhibit the formation of stress granules or protein aggregates, whereby the composition is capable of exhibiting excellent efficacy against neurodegenerative diseases, which are TDP -43 proteinous diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical composition for preventing or treating neurodegenerative diseases containing graphene quantum dots as an active ingredient

[0001] The present invention relates to a pharmaceutical composition for preventing or treating a neurodegenerative disease, comprising graphene quantum dots as an active ingredient, and more specifically, to a pharmaceutical composition for preventing or treating a neurodegenerative disease that is a TDP-43 protein disease.

[0002] This invention claims the benefit of priority from Korean Patent Application No. 10-2023-0069199, filed May 30, 2023, and Korean Patent Application No. 10-2023-0161553, filed November 20, 2023, the entire contents of which are incorporated herein by reference.

[0003]

[0004] A neurodegenerative disease is a degenerative disease that occurs with age, and it refers to a disease that occurs in the brain or spinal cord. It is a disease that is manifested by the gradual loss of structure and function of specific groups of brain cells in the brain and spinal cord due to unknown causes, genetic defects, or environmental factors. It is known that the death or damage of nerve cells caused by the above-mentioned neurodegenerative disease causes problems in the formation or function of synapses, which transmit information between nerve cells, which are most important for the transmission of information in the nervous system, and abnormal increases or decreases in the electrical activity of the nerves. Since nerve cells in the brain and spinal cord perform very diverse functions depending on their location, damage to nerve cells in a specific area causes characteristic dysfunction, and the clinical picture is also very diverse depending on the form of this dysfunction.

[0005] Meanwhile, TDP-43 protein-mediated diseases are a type of neurodegenerative disease, and TDP-43 (TAR DNA-binding protein 43, transactive response DNA-binding protein 43 kDa) is a ubiquitin-positive inclusion body. Because TDP-43 inclusion bodies are not amyloid deposits, TDP-43 protein-mediated diseases are distinct from most other neurodegenerative disorders. The effectiveness of graphene quantum dots in these TDP-43 protein-mediated diseases, and the use of graphene quantum dots for the prevention or treatment of neurodegenerative diseases, have not been reported.

[0006] TDP-43 is a protein encoded by the TARDBP gene in humans. TDP-43 is a transcriptional repressor that inhibits HIV-1 transcription by binding to TAR DNA, a regulatory element of the HIV-1 long terminal repeat (LTR) contained in the chromosome. It is also known to regulate alternate splicing of the CFTR gene and apA-II gene. Furthermore, TDP-43 binds to both DNA and RNA, exhibiting diverse functions in transcriptional repression, pre-mRNA splicing, and translational regulation. In spinal motor neurons, TDP-43 is known to be a human low molecular weight neurofilament (hNFL) mRNA-binding protein. It is known as an activity-responsive factor in the dendritic spines of hippocampal neurons, possibly playing a role in the regulation of neuronal mRNA stability, transport, and local translation.

[0007] TDP-43 is 414 amino acid residues long and consists of four domains: the N-terminal domain (NTD), RNA recognition motif (RRM) 1, RRM2, and the C-terminal domain (CTD). The NTD is the N-terminal domain spanning residues 1–75, which is known to form dimers or oligomers. RRM1 and RRM2 are domains required for binding target RNA and DNA, respectively. The CTD is known to be involved in protein-protein interactions and harbors the majority of disease-associated mutations.

[0008] In particular, the CTD is reported to play a crucial role in the pathogenic behavior of TDP-43. Specifically, the disordered structure of the CTD can transform into a structure rich in amyloid-like beta sheets, resulting in prion-like properties. Furthermore, C-terminal fragments (CTFs) are common products of diseased neurons and are known to be highly toxic.

[0009] The purpose of the present invention is to provide a pharmaceutical composition for preventing or treating a degenerative neurological disease, which comprises graphene quantum dots as an active ingredient.

[0010] The present invention aims to provide a kit comprising a pharmaceutical composition for preventing or treating a neurodegenerative disease, which comprises graphene quantum dots as an active ingredient; and instructions for using the pharmaceutical composition for preventing or treating a neurodegenerative disease.

[0011] However, the technical problems to be solved by the present invention are not limited to the problems mentioned above, and other problems not mentioned can be clearly understood by a person having ordinary skill in the technical field to which the present invention belongs from the description below.

[0012]

[0013] To achieve the above purpose, the present invention provides a pharmaceutical composition for preventing or treating a degenerative neurological disease, which contains graphene quantum dots as an active ingredient.

[0014] In one embodiment of the present invention, the graphene quantum dots may have an average diameter of 1 to 100 nm, but is not limited thereto.

[0015] In another embodiment of the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases of amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0016] In another embodiment of the present invention, the graphene quantum dots can inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates, but are not limited thereto.

[0017] In addition, the present invention provides a kit comprising a pharmaceutical composition for preventing or treating a neurodegenerative disease, which comprises graphene quantum dots as an active ingredient; and instructions for using the pharmaceutical composition for preventing or treating the neurodegenerative disease.

[0018] In one embodiment of the present invention, the graphene quantum dots may have an average diameter of 1 to 100 nm, but is not limited thereto.

[0019] In another embodiment of the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0020] In another embodiment of the present invention, the graphene quantum dots can inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates, but are not limited thereto.

[0021] In addition, the present invention provides a method for preventing or treating a degenerative neurological disease, comprising a step of administering a composition comprising graphene quantum dots as an active ingredient to a subject in need thereof.

[0022] In addition, the present invention provides a composition comprising graphene quantum dots as an active ingredient for use in the prevention or treatment of neurodegenerative diseases.

[0023] In addition, the present invention provides a use for preparing a preparation for the prevention or treatment of a neurodegenerative disease of a composition comprising graphene quantum dots as an active ingredient.

[0024]

[0025] The pharmaceutical composition of the present invention can prevent or treat neurodegenerative diseases by controlling the formation of stress granules or protein aggregates.

[0026] The kit of the present invention can prevent or treat neurodegenerative diseases by controlling the formation of stress granules or protein aggregates.

[0027] The graphene quantum dots of the present invention can prevent, treat or improve neurodegenerative diseases by controlling the formation of stress granules or protein aggregates.

[0028] The graphene quantum dots of the present invention can delay the onset of degenerative neurological diseases and extend lifespan through effective improvement in neurological scores.

[0029] The graphene quantum dots of the present invention can improve muscle strength or exercise performance by preventing the death of motor neurons.

[0030] The graphene quantum dots of the present invention can prevent persistent nerve damage caused by an immune response by regulating the activation of astrocytes and microglia.

[0031] The graphene quantum dots of the present invention can be effective as a therapeutic agent for diseases caused by the formation of stress granules, TDP-43 protein aggregates, or FUS (Fused in sarcoma) protein aggregates.

[0032]

[0033] The present invention encompasses the use of graphene quantum dots as a therapeutic agent for neurodegenerative diseases, preferably as a therapeutic agent for TDP-43 protein-related diseases, and more preferably as a therapeutic agent for amyotrophic lateral sclerosis or frontotemporal dementia. Graphene quantum dots exert the effects of delaying the onset of the diseases, extending lifespan, improving muscle strength, and preventing persistent nerve damage caused by excessive immune responses by controlling the formation of stress granules or protein aggregates, which are the main pathogenic mechanisms of the diseases.

[0034]

[0035] Figure 1a shows the design of TDP-43 protein, TDP-43 mutant proteins (TDP-43-A315T, TDP-43-Q331K), and TDP-43 C-terminal fragments (CTF-35, CTF-25, CTF-23, CTF-16).

[0036] Figures 1b and 1c show the sequences of TDP-43 protein, TDP-43 mutant proteins (TDP-43-A315T, TDP-43-Q331K), and TDP-43 C-terminal fragments (CTF-35, CTF-25, CTF-23, CTF-16).

[0037] Figure 1d shows the results of preventing cell death according to the administration of GQD when TDP-43 protein (TDP-43-WT), TDP-43 mutant protein (TDP-43-A315T or TDP-43-Q331K), or TDP-43 C-terminal fragment (CTF-35, CTF-25, CTF-23, or CTF-16) was overexpressed in a motor neuron (NSC34 cell line) model.

[0038] Figures 2a and 2b show the results of inhibiting stress granule formation of G3BP1 (also referred to as G3BP) when 10 μM sodium arsenite (NaAsO2) was administered to a HeLa cell model and GQDs were administered during the reaction.

[0039] Figures 2c and 2d show the results of inhibiting stress granule formation of G3BP1 (also referred to as G3BP) when GQDs were administered before administering 10 μM sodium arsenite (NaAsO2) to a HeLa cell model.

[0040] Figures 2e and 2f show the results of inhibiting the formation of stress granules of TIA1 when 10 μM sodium arsenite (NaAsO2) was administered to a HeLa cell model and GQDs were administered during the reaction.

[0041] Figures 2g and 2h show the results of inhibiting the formation of stress granules of TIA1 when GQDs were administered before administering 10 μM sodium arsenite (NaAsO2) to a HeLa cell model.

[0042] Figure 3a shows the results of inhibiting the formation of stress granules of TDP-43 when GQDs were administered before administering 10 μM sodium arsenite (NaAsO2) to a HeLa cell model.

[0043] Figure 3b shows the results of inhibition of TDP-43 stress granule formation when 10 μM sodium arsenite (NaAsO2) was administered to a HeLa cell model and GQDs were administered during the reaction.

[0044] Figure 4a shows the results of inhibiting stress granule formation when GQDs were administered to cell models overexpressing TDP-43 protein (TDP-43-WT) or TDP-43 mutant proteins (TDP-43-A315T or TDP-43-Q331K) when sorbitol was administered.

[0045] Figure 4b shows the results of inhibiting the formation of stress granules or protein aggregates when GQDs were administered to cell models overexpressing TDP-43 protein (TDP-43-WT), TDP-43 mutant protein (TDP-43-A315T or TDP-43-Q331K), or TDP-43 C-terminal fragment (CTF-35, CTF-25, CTF-23, or CTF-16), respectively.

[0046] Figure 5 shows the results of delayed disease onset and improved survival when GQD was administered to TDP-43-A315T mice.

[0047] Figure 6 shows the results of muscle strength improvement measured by the rotarod test (latency to fall) and grip strength when GQD was administered to TDP-43-A315T mice.

[0048] Figures 7a and 7b show the results of improvement in motor neuron death in the spinal cord and changes in the number of dysmorphic neurons when GQDs were administered to TDP-43-A315T mice.

[0049] Figures 7c and 7d show the results of inhibition of microglia (expressed as Iba1) and astrocyte (expressed as GFAP) activity when GQDs were administered to TDP-43-A315T mice.

[0050] Figure 8 shows the results of dissolution of TDP-43 protein aggregates in the spinal cord when GQDs were administered to TDP-43-A315T mice.

[0051] Figure 9a shows the results of delayed disease onset and improved survival when GQDs were administered to TDP-43-WT mice.

[0052] Figure 9b shows the results of muscle strength improvement measured by the rotarod test (latency to fall) and grip strength when GQD was administered to TDP-43-WT mice.

[0053] Figures 10a and 10b show the results of improvement in motor neuron death in the spinal cord and changes in the number of dysmorphic neurons when GQDs were administered to TDP-43-WT mice.

[0054] Figures 10c and 10d show the results of inhibition of microglia (expressed as Iba1) and astrocyte (expressed as GFAP) activity when GQDs were administered to TDP-43-WT mice.

[0055] Figure 11 shows the results of dissolution of TDP-43 protein aggregates in the spinal cord when GQDs were administered to TDP-43-WT mice.

[0056] Figure 12a shows the results of preventing cell death according to the administration of GQD when FUS protein (FUS-WT) or FUS mutant protein (FUS-G504Wfs, FUS-R495X) was overexpressed in a motor neuron cell (NSC34 cell line) model.

[0057] Figure 12b shows the results of inhibiting the formation of FUS protein aggregates when GQDs were administered before sorbitol was administered to a HeLa cell model.

[0058] Figure 12c shows the results of inhibiting the formation of FUS protein aggregates when sorbitol was administered to a HeLa cell model and GQDs were administered during the reaction.

[0059] Figure 12d shows the results of inhibition of stress granule formation when sorbitol was administered to a cell model overexpressing FUS protein (FUS-WT) or FUS mutant proteins (FUS-G504Wfs, FUS-R495X) and when GQDs were administered.

[0060] Figure 13a shows the results of muscle strength improvement measured by measuring grip strength according to whether or not GQD was administered in C9orf72 mice.

[0061] Figures 13b and 13c show the results of improvement in motor neuron death in the spinal cord and changes in the number of dysmorphic neurons when GQDs were administered to C9orf72 mice.

[0062] Figures 13d and 13e show the results of inhibition of microglia (represented by Iba1) and astrocyte (represented by GFAP) activity when GQDs were administered to C9orf72 mice.

[0063] Figure 14a shows the results of dissolution of poly-GR protein aggregates in the spinal cord when GQDs were administered to C9orf72 mice.

[0064] Figure 14b shows the results of dissolution of TDP-43 protein aggregates in the spinal cord when GQDs were administered to C9orf72 mice.

[0065]

[0066] The present invention provides a pharmaceutical composition for preventing or treating a degenerative neurological disease, comprising graphene quantum dots as an active ingredient.

[0067] In the present invention, the graphene quantum dots may have an average diameter of 1 to 100 nm, but are not limited thereto.

[0068] In the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases among amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0069] In the present invention, the graphene quantum dots can inhibit one or more proteins selected from the group consisting of TDP-43 (which may be described as TDP-43-WT), TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35 (which may be described as CTF-35), TDP-43 C-terminal fragment-25 (which may be described as CTF-25), TDP-43 C-terminal fragment-23 (which may be described as CTF-23), and TDP-43 C-terminal fragment-16 (which may be described as CTF-16) from forming stress granules or protein aggregates, but are not limited thereto.

[0070] In the present invention, graphene means a polycyclic aromatic molecule formed by a plurality of carbon atoms covalently bonded to each other, and the carbon atoms connected by the covalent bonds form a 6-membered ring as a basic repeating unit, but may also mean a 5-membered ring and / or a 7-membered ring, but is not limited thereto.

[0071] In the present invention, graphene quantum dots (GQDs) are the smallest form of graphene, and refer to graphene with nano-sized fragments. Specifically, the graphene quantum dots refer to graphene particles having a width, length, and height of several nm, manufactured through appropriate processing, and may refer to a semiconductor crystal composed of graphene, but are not limited thereto.

[0072] In the present invention, graphene quantum dots can be obtained by thermo-oxidative cutting of carbon fiber, carbon black, graphite, carbon nanotube, etc., but are not limited thereto.

[0073] In the present invention, the thickness, diameter, and height of the graphene quantum dot may be greater than 0 and less than 100 nm, but are not limited thereto.

[0074] In the present invention, the graphene quantum dots have an average diameter of 1 to 100 nm, 1 to 90 nm, 1 to 80 nm, 1 to 70 nm, 1 to 60 nm, 1 to 50 nm, 1 to 40 nm, 1 to 30 nm, 1 to 20 nm, 1 to 10 nm, 1 to 9 nm, 1 to 8 nm, 1 to 7 nm, 1 to 6 nm, 1 to 5 nm, 1 to 4 nm, 1 to 3 nm, 1 to 2 nm, 2 to 10 nm, 2 to 9 nm, 2 to 8 nm, 2 to 7 nm, 2 to 6 nm, 2 to 5 nm, 2 to 4 nm, 2 to 3 nm, 3 to 10 nm, 3 to 9 nm, 3 to 8 nm, 3 to 7 nm, 3 to 6 nm, 4 The average diameter may be, but is not limited to, 10 nm, 4 to 9 nm, 4 to 8 nm, 4 to 7 nm, 4 to 6 nm, 4 to 5 nm, 5 to 10 nm, 5 to 9 nm, 5 to 8 nm, 5 to 7 nm, 5 to 6 nm.

[0075] In the present invention, graphene quantum dots may exist in solid or liquid form. The solvate may include non-aqueous solvents such as ethanol, isopropanol, DMSO, acetic acid, ethanolamine, and ethyl acetate, or may include water as a solvent incorporated into the crystal lattice. Solvates in which water is incorporated into the crystal lattice are typically referred to as "hydrates." The present invention includes, but is not limited to, all such solvates.

[0076] In the present invention, the graphene quantum dots may inhibit proteins from forming stress granules or protein aggregates, and preferably, one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 may inhibit proteins from forming stress granules or protein aggregates.

[0077] In the present invention, TDP-43 (TAR DNA binding protein 43, transactive response DNA binding protein 43 kDa) (also referred to as TDP-43-WT) is a protein having a length of 414 amino acid residues and encoded by the TARDBP gene. It may have the amino acid sequence of SEQ ID NO: 1, but is not limited thereto.

[0078] In the present invention, TDP-43-A315T is a mutant protein having a length of 414 amino acid residues and in which the 315th amino acid residue of TDP-43 is substituted from A to T. It may have the amino acid sequence of SEQ ID NO: 2, but is not limited thereto.

[0079] In the present invention, TDP-43-Q331K is a mutant protein having a length of 414 amino acid residues and in which the 331st amino acid residue of TDP-43 is substituted from Q to K. It may have the amino acid sequence of SEQ ID NO: 3, but is not limited thereto.

[0080] In the present invention, the TDP-43 C-terminal fragment (C-terminal fragment)-35 is a C-terminal fragment protein having a length of 325 amino acid residues and truncated by 35 kDa from the C-terminus of TDP-43. It may have the amino acid sequence of SEQ ID NO: 4, but is not limited thereto.

[0081] In the present invention, the TDP-43 C-terminal fragment-25 is a C-terminal fragment protein having a length of 245 amino acid residues and truncated by 25 kDa from the C-terminus of TDP-43. It may have the amino acid sequence of SEQ ID NO: 5, but is not limited thereto.

[0082] In the present invention, the TDP-43 C-terminal fragment-23 is a C-terminal fragment protein having a length of 206 amino acid residues and truncated by 23 kDa from the C-terminus of TDP-43. It may have the amino acid sequence of SEQ ID NO: 6, but is not limited thereto.

[0083] In the present invention, the TDP-43 C-terminal fragment-16 is a C-terminal fragment protein having a length of 149 amino acid residues and truncated by 16 kDa from the C-terminus of TDP-43. It may have the amino acid sequence of SEQ ID NO: 7, but is not limited thereto.

[0084] In the present invention, the graphene quantum dots may suppress the formation of stress granules or protein aggregates by overexpression of one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16, but are not limited thereto.

[0085] In the present invention, the graphene quantum dots may inhibit one or more proteins selected from the group consisting of FUS (Fused in sarcoma), FUS-G504Wfs, and FUS-R495X from forming stress granules or protein aggregates, but are not limited thereto.

[0086] In the present invention, the graphene quantum dots may suppress the formation of stress granules or protein aggregates by overexpression of one or more proteins selected from the group consisting of FUS, FUS-G504Wfs, and FUS-R495X, but are not limited thereto.

[0087] In the present invention, the neurodegenerative disease may be a disease caused by the formation of either stress granules or protein aggregates.

[0088] In the present invention, the neurodegenerative disease may be a disease that occurs when there is a possibility that either stress granules or protein aggregates are formed.

[0089] In the present invention, the neurodegenerative disease may be a disease caused by one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 forming stress granules or protein aggregates.

[0090] In the present invention, the neurodegenerative disease may be a disease caused by overexpression of one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16, thereby forming stress granules or protein aggregates.

[0091] In the present invention, the neurodegenerative disease may be a disease caused by a mutation in the TDP-43 gene.

[0092] In the present invention, the neurodegenerative disease may be a disease caused by the production of a TDP-43 protein variant.

[0093] In the present invention, the neurodegenerative disease may be a disease in which a functional disorder is caused by multiple genetic mutations due to overproduction of TDP-43.

[0094] In the present invention, the neurodegenerative disease may be a disease caused by a change in a single DNA base sequence of the TDP-43 gene, which causes overexpression of a protein due to a disorder in the gene self-regulation function.

[0095] In the present invention, the degenerative neurological disease may be a disease caused by abnormal expression of other genes related to frontotemporal dementia or amyotrophic lateral sclerosis.

[0096] In the present invention, the neurodegenerative disease may be a disease caused by one or more proteins selected from the group consisting of FUS, FUS-G504Wfs, and FUS-R495X forming stress granules or protein aggregates.

[0097] In the present invention, the neurodegenerative disease may be a disease caused by overexpression of one or more proteins selected from the group consisting of FUS, FUS-G504Wfs, and FUS-R495X, thereby forming stress granules or protein aggregates.

[0098] In the present invention, the degenerative neurological disease may be a disease caused by a mutation in the FUS gene.

[0099] In the present invention, the neurodegenerative disease may be a disease caused by the production of a FUS protein variant.

[0100] In the present invention, the neurodegenerative disease is amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, frontotemporal dementia (FTD), Alzheimer's disease (AD), Lewy body disease (LBD), Huntington's disease (HD), argyrophilic grain disease (AGD), Parkinson's disease (PD), chronic traumatic encephalopathy (CTE), limbic-predominant age-related TDP-43 encephalopathy (LATE), and multiple sclerosis (MS). It may be at least one selected from the group consisting of stroke, amyloidosis, and fibrosis, and preferably at least one selected from the group consisting of amyotrophic lateral sclerosis, frontotemporal dementia, Alzheimer's disease, Lewy body disease, Huntington's disease, gravid grain disease, Parkinson's disease, chronic traumatic encephalopathy, and limbic-predominant age-related TDP-43 encephalopathy, and more preferably, but not limited to, amyotrophic lateral sclerosis or frontotemporal dementia.

[0101] In the present invention, the neurodegenerative disease may be a TDP-43 (TAR DNA binding protein 43) protein disease.

[0102] In the present invention, the TDP-43 protein may contribute to the formation of a clump of proteins, RNA, DNA, etc. collectively called stress granules when cells are placed in a stress situation due to internal / external factors such as oxidation, aging, and toxicity, but is not limited thereto.

[0103] In the present invention, the TDP-43 protein may regulate, but is not limited to, mRNA stability, transport, and local translation in neurons in the central nervous system.

[0104] In the present invention, the TDP-43 protein disease may be selected from the group consisting of amyotrophic lateral sclerosis, frontotemporal dementia, arginine particle disease, Alzheimer's disease, ALS-Parkinsonian dementia complex in Guam, corticobasal degeneration, dementia with Lewy bodies, Huntington's disease, Lewy body disease, motor neuron disease, frontotemporal lobar degeneration (FTLD), frontotemporal lobar degeneration due to ubiquitin-positive inclusions, hippocampal sclerosis, inclusion body myopathy, inclusion body myositis, Parkinson's disease, Parkinsonian dementia, Parkinson-dementia complex in the Gii Peninsula, and Pick's disease, and preferably may be amyotrophic lateral sclerosis or frontotemporal dementia, but is not limited thereto.

[0105] In the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases among amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0106] In the present invention, prevention includes all acts that inhibit or delay the occurrence of a degenerative neurological disease.

[0107] In the present invention, treatment includes all actions that improve or beneficially change the symptoms of an individual suffering from a degenerative neurological disease.

[0108] In the present invention, an individual refers to a subject to which the composition of the present invention can be administered, and there is no limitation on the subject.

[0109] The pharmaceutical composition of the present invention may further comprise one or more pharmaceutically acceptable carriers in addition to the graphene quantum dots according to the present invention for administration. Pharmaceutically acceptable carriers may include saline solution, sterile water, Ringer's solution, buffered saline, dextrose solution, maltodextrin solution, glycerol, ethanol, and mixtures of one or more of these components. If necessary, other conventional additives such as antioxidants, buffers, and bacteriostatic agents may be added. In addition, diluents, dispersants, surfactants, binders, and lubricants may be additionally added to formulate the composition into injectable formulations such as aqueous solutions, suspensions, and emulsions, pills, capsules, granules, or tablets. Accordingly, the pharmaceutical composition of the present invention may be in the form of patches, solutions, pills, capsules, granules, tablets, suppositories, and the like. These preparations can be prepared by conventional methods used in formulation in the art or by methods disclosed in Remington's Pharmaceutical Science (latest edition), Mack Publishing Company, Easton PA, and can be formulated into various preparations depending on each disease or ingredient.

[0110] The pharmaceutical composition of the present invention can be administered orally or parenterally (e.g., intravenously, subcutaneously, intraperitoneally, or topically) depending on the intended method, and the dosage range varies depending on the patient's weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and severity of the disease.

[0111] The daily dosage of the graphene quantum dots according to the present invention is about 1 to 1000 mg / kg, preferably 5 to 100 mg / kg, and can be administered once or several times a day.

[0112] The pharmaceutical composition of the present invention may further include one or more active ingredients exhibiting the same or similar efficacy in addition to the graphene quantum dots according to the present invention.

[0113]

[0114] The present invention provides a method for preventing or treating a neurodegenerative disease comprising administering a therapeutically effective amount of graphene quantum dots according to the present invention.

[0115] In the present invention, the neurodegenerative disease may be a TDP-43 protein disease of at least one of amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0116] In the present invention, the graphene quantum dots may inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates.

[0117] In the present invention, all of the above-described matters regarding graphene quantum dots, degenerative neurological diseases, TDP-43 protein diseases, prevention, and treatment are directly applicable to the method for preventing or treating degenerative neurological diseases of the present invention.

[0118] In the present invention, the therapeutically effective amount refers to the amount of the graphene quantum dots effective in preventing or treating a degenerative neurological disease.

[0119] In the present invention, the method for preventing or treating a neurodegenerative disease involves administering the graphene quantum dots, thereby not only treating the disease itself before its symptoms appear, but also inhibiting or avoiding its symptoms. In managing the disease, the prophylactic or therapeutic dosage of a specific active ingredient will vary depending on the nature and severity of the disease or condition, and the route of administration of the active ingredient. The dosage and frequency of administration will vary depending on the age, weight, and response of the individual patient. An appropriate dosage regimen can be readily selected by one skilled in the art, taking these factors into account.

[0120] In the present invention, the method for preventing or treating a neurodegenerative disease may further include administering a therapeutically effective amount of an additional active agent helpful in treating the disease together with the graphene quantum dots, and the additional active agent may exhibit a synergistic or auxiliary effect together with the graphene quantum dots.

[0121]

[0122] The present invention provides a health functional food for improving exercise performance and preventing or improving degenerative neurological diseases, comprising graphene quantum dots or a food-based salt thereof.

[0123] In the present invention, the degenerative neurological disease may be a TDP-43 protein disease.

[0124] In the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0125] In the present invention, the graphene quantum dots may inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates.

[0126] In the present invention, all of the aforementioned matters regarding graphene quantum dots, degenerative neurological diseases, TDP-43 protein diseases, and prevention thereof are applied to the health functional food of the present invention.

[0127] In the present invention, the meaning of food-related acceptable may be that the compound or composition does not cause serious irritation to an individual, cell, tissue, etc. to which it is administered and does not damage the biological activity and physical properties of the compound.

[0128] In the present invention, a food-wise acceptable salt may be a salt prepared using a specific compound according to the present invention and a relatively non-toxic acid or base.

[0129] In the present invention, exercise performance ability may mean the ability to perform physical movements performed in daily life or sports quickly, strongly, for a long time, and skillfully.

[0130] In the present invention, improvement includes any act that improves or beneficially changes the symptoms of an individual suffering from a degenerative neurological disease.

[0131] In the present invention, a health functional food refers to a food manufactured or processed by using a specific ingredient as a raw material or by extracting, concentrating, refining, mixing, etc. a specific ingredient contained in a food raw material for the purpose of health supplementation, and refers to a food designed and processed so that the above-mentioned ingredient can sufficiently exert a bioregulatory function, such as biological defense, biological rhythm regulation, disease prevention and recovery, on the body, and the above-mentioned health food composition can perform functions related to disease prevention and disease recovery.

[0132] In the present invention, the health functional food can be manufactured and processed in the form of tablets, capsules, powders, granules, liquids, pills, etc. for the purpose of preventing or improving degenerative neurological diseases.

[0133] In the present invention, a health functional food refers to a food manufactured and processed using raw materials or ingredients having functionality useful to the human body according to Act No. 6727 on Health Functional Foods, and may mean ingestion for the purpose of obtaining a useful effect for health purposes such as regulating nutrients for the structure and function of the human body or physiological action.

[0134] In the present invention, health functional foods may include conventional food additives, and their suitability as food additives is determined by the specifications and standards for the relevant item in accordance with the general provisions and general test methods of the Food Additives Code approved by the Ministry of Food and Drug Safety, unless otherwise specified.

[0135] In the present invention, the items listed in the food additive code include, but are not limited to, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, sucrose pigment, and guar gum; and mixed preparations such as sodium L-glutamate preparations, noodle additive alkaline agents, preservative preparations, and tar color preparations. For example, a health functional food in tablet form can be prepared by mixing the compound with an excipient, a binder, a disintegrant, and other additives, granulating the mixture using a conventional method, and then adding a lubricant, etc. to perform compression molding, or directly compressing the mixture. In addition, the health functional food in tablet form can contain a flavoring agent, etc., if necessary.

[0136] In the present invention, health functional foods may include beverages, meat, chocolate, food, confectionery, pizza, ramen, other noodles, gum, candy, ice cream, alcoholic beverages, vitamin complexes, and health supplements.

[0137]

[0138] The present invention provides a kit comprising a pharmaceutical composition for preventing or treating a neurodegenerative disease, comprising graphene quantum dots as an active ingredient; and instructions for using the pharmaceutical composition for preventing or treating a neurodegenerative disease.

[0139] In the present invention, the graphene quantum dots may have an average diameter of 1 to 100 nm, but are not limited thereto.

[0140] In the present invention, the neurodegenerative disease may be, but is not limited to, one or more TDP-43 protein diseases, such as amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

[0141] In the present invention, the graphene quantum dots may inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates, but are not limited thereto.

[0142] In the present invention, all of the above-described matters regarding graphene quantum dots, degenerative neurological diseases, TDP-43 protein diseases, prevention and treatment are applied as is to the kit of the present invention.

[0143] In the present invention, the kit is not limited in its specific form as long as it can achieve the purpose of preventing, improving, or treating a degenerative neurological disease, and may include any components and devices for manufacturing, storing, administering, etc., the composition according to the present invention without limitation. In addition, the kit may include a description describing the general characteristics, usage method, storage method, administration dosage, etc. of the composition of the present invention.

[0144] In the present invention, the kit may include other components, devices, substances, etc. typically required to enhance the preventive or therapeutic effects of degenerative neurological diseases. Furthermore, all components included in the kit may be used more than once without limitation, there are no restrictions on the order in which each substance is used, and the application of each substance may be performed simultaneously or sequentially.

[0145] In the present invention, the kit may include a container in addition to the formulation and instructions. The container may serve to package the components, and may also serve to store and secure them. The container may be formed of a material such as a bottle, a tub, a sachet, an envelope, a tube, an ampoule, or the like, and may be formed partially or wholly from plastic, glass, paper, foil, wax, or the like. The container may be equipped with a completely or partially detachable stopper, which may initially be part of the container or may be attached to the container by mechanical, adhesive, or other means, and may also be equipped with a stopper that allows access to the contents by means of a syringe. The kit may include an outer package, which may include, but is not limited to, instructions for the use of the components.

[0146] In the present invention, the instructions may specifically include conditions for handling, storage, effects, administration methods, and administration dosages of the composition according to the present invention, but are not limited thereto.

[0147]

[0148] The present invention provides a method for preventing or treating a degenerative neurological disease, comprising administering to a subject in need thereof a composition comprising graphene quantum dots as an active ingredient.

[0149] The present invention provides a composition comprising graphene quantum dots as an active ingredient for use in the prevention or treatment of neurodegenerative diseases.

[0150] The present invention provides a use for preparing a preparation for the prevention or treatment of a neurodegenerative disease using a composition comprising graphene quantum dots as an active ingredient.

[0151]

[0152] The present invention provides graphene quantum dots for use in the treatment of neurodegenerative diseases.

[0153] The present invention provides a composition comprising graphene quantum dots for use as a medicine.

[0154] The present invention provides a drug comprising graphene quantum dots.

[0155] The present invention provides the use of compound graphene quantum dots for the manufacture of a medicament for treating neurodegenerative diseases.

[0156] The present invention provides a pharmaceutical composition comprising graphene quantum dots.

[0157] The present invention provides a method of treating an animal having a neurodegenerative disease, comprising administering to the animal an effective amount of graphene quantum dots.

[0158] The present invention provides a medicine (therapeutic agent) composed of graphene quantum dots.

[0159] The present invention provides the use of graphene quantum dots for the preparation of medicaments for the treatment of neurodegenerative diseases.

[0160] The present invention provides the use of graphene quantum dots in the manufacture of a pharmaceutical agent for treating neurodegenerative diseases.

[0161] The present invention provides a treatment for a neurodegenerative disease characterized by containing graphene quantum dots.

[0162] The present invention provides a composition for treating a neurodegenerative disease, characterized in that it contains graphene quantum dots.

[0163] The present invention provides a pharmaceutical composition for treating a neurodegenerative disease comprising graphene quantum dots together with a pharmaceutically acceptable excipient.

[0164] The present invention provides the use of graphene quantum dots for the manufacture of pharmaceuticals for the treatment of neurodegenerative diseases.

[0165] In the present invention, all of the matters described above regarding graphene quantum dots and degenerative neurological diseases are applied as is to the present invention.

[0166]

[0167] Hereinafter, preferred examples are presented to aid in understanding the present invention. However, the following examples are provided solely to facilitate a better understanding of the present invention, and the scope of the present invention is not limited by the following examples.

[0168]

[0169] Experimental Example 1. Fabrication of Graphene Quantum Dots, Cell Models, and Animal Models

[0170] 1-1. Fabrication of graphene quantum dots (GQDs)

[0171] Carbon fibers were placed in a strong acid solution of sulfuric acid and nitric acid in a 3:1 ratio and heated at 80°C for 24 hours (thermo-oxidation process). After diluting the solution, the acid was removed by dialysis through a regenerated nitrocellulose membrane (Cat#: 06-680-2G; MWCO 1,000 Dalton; Fisher Sicentific), vacuum-filtered through a porous inorganic membrane filter (Cat#: 6809-5002; Whatman-Anodisc 47; GE Healthcare), and then freeze-dried to produce graphene quantum dots in powder form. The graphene quantum dot powder was redispersed in distilled water and used in the experiment.

[0172]

[0173] 1-2. Cell model production

[0174] Cell models were constructed by transfecting HeLa cells with plasmids harboring mutant TDP-43 and FUS proteins (Fig. 1a). Cell death induced by overexpression of TDP-43 and FUS mutant proteins was analyzed by direct counting. The formation of stress granules and TDP-43 protein aggregates was measured by fluorescence microscopy using antibodies against TIA1, G3BP1 (also referred to as G3BP), and TDP-43 after treatment with 10 μM sodium arsenite (NaAsO2) or 0.4 M sorbitol for 30 minutes to 30 hours, respectively.

[0175]

[0176] 1-3. Animal model production

[0177] The efficacy of the drug was evaluated by administering GQDs to three mouse models (TDP-43-WT, TDP-43-A315T, and C9orf72) associated with TDP-43 protein aggregates. Specifically, the mouse models used were TDP-43-WT (Jackson Lab, (#016144), Tg(Prnp-TARDBP)4Jlel / J), TDP-43-A315T (Jackson Lab, (#016143), B6SJL-Tg(Prnp-TARDBP*A315T)23Jlel / J), and C9orf72 (Jackson Lab, (#029099), FVB / NJ-Tg(C9orf72)500Lpwr / J). The TDP-43-WT and TDP-43-A315T mouse models overexpress the normal TDP-43 protein and the A315T mutant protein, respectively, in motor neurons and form aggregates, and exhibit an average survival period of approximately 170 days. The C9orf72 mouse model is a mouse in which five types of dipeptide repeats (DPRs) such as Poly-GR / PR / GA / GP / PA are generated by repetitive insertions of GGGGCC hexanucleotides. DPRs accumulate in motor neurons and exhibit pathological mechanisms, and are known to induce the formation of TDP-43 protein aggregates in particular. In addition to the ALS (Amyotrophic Lateral Sclerosis) phenotype, this mouse model exhibits the phenotype of frontotemporal dementia.

[0178] After administering GQD (2 mg / kg, ip, weekly) to three mouse models, neurological scores such as onset and survival were analyzed, and behavioral indices such as body weight, rotarod test, and grip strength were observed. For neurological score measurement, the neurological score was measured daily, and a neurological score of 0.5 was defined as disease onset, and a neurological score of 4 was defined as survival. For behavioral indices analysis, body weight was measured daily, and rotarod test and grip strength were measured once a week. For tissue indices analysis, motor neurons were analyzed through Nissl staining in the ventral horn of the spinal cord and the motor cortex of the cerebrum, and the activity of astrocytes and microglia was measured by analyzing fluorescent images obtained using antibodies to GFAP and Iba1, respectively, in the same areas.

[0179]

[0180] Experimental Example 2. Inhibition of intracellular aggregate formation (stress granules and protein aggregates) by GQDs in a cell model.

[0181] When 10 μM sodium arsenite (NaAsO2) was administered to normal HeLa cells, stress granules in which G3BP1 (also referred to as G3BP) protein aggregates were observed after 30 minutes. At this time, when GQDs were added during the reaction (Figs. 2a and 2b) or administered in advance (Figs. 2c and 2d), the formation of stress granules was inhibited.

[0182] In addition, when 10 μM sodium arsenite (NaAsO2) was administered to normal HeLa cells, stress granules in which TIA1 protein was aggregated were observed after 30 minutes. At this time, when GQDs were added during the reaction (Fig. 2e and Fig. 2f) or administered in advance (Fig. 2g and Fig. 2h), the formation of stress granules was inhibited.

[0183] Additionally, TDP-43 protein also forms stress granules together with G3BP1 (also referred to as G3BP) protein, and stress granules containing TDP-43 were resolved or inhibited by treatment with GQDs (Figs. 3a and 3b).

[0184] In a cell model overexpressing TDP-43 mutant protein, when 0.4 M sorbitol was treated, stress granules were formed with G3BP1 (also referred to as G3BP) protein, and the formation of stress granules was controlled by GQD (Fig. 4a). When TDP-43 C-terminal fragments (CTF (C-terminal fragments)-35, CTF-25, CTF-23, CTF-16) were overexpressed, protein aggregates in the form of granules were formed in the cytoplasm on their own without any separate stress, but were resolved by GQD (Fig. 4b).

[0185] Additionally, it was confirmed that the death of motor neurons (NSC34 cell line) caused by overexpression of TDP-43 protein, TDP-43 mutant protein, or TDP-43 C-terminal fragment was also inhibited by GQD (Fig. 1d).

[0186]

[0187] Experimental Example 3. GQD-induced lifespan extension and improved exercise performance in the TDP-43-A315T mouse model.

[0188] A drug administration experiment was conducted with TDP-43-A315T mice, consisting of 40-day-old males or 60-day-old females, by intraperitoneal injection of GQD at a weekly dose of 2 mg / kg. In the male group, disease onset occurred at 54.6 ± 2.7 days in vehicle-treated TDP-43-A315T mice (n = 12), while disease onset occurred at 61.8 ± 3.1 days in GQD-treated TDP-43-A315T mice (n = 12). Consequently, when GQD was administered, the disease onset time was delayed by an average of 7.2 days (13.2% improvement). In the female group, disease onset occurred at 74.4 ± 3.6 days in vehicle-treated TDP-43-A315T mice (n = 12), while disease onset occurred at 86.7 ± 2.2 days in GQD-treated TDP-43-A315T mice (n = 12). Consequently, when GQDs were administered, disease onset was delayed by an average of 12.3 days (16.5% improvement).

[0189] Analysis of the average survival time of the mice showed that in the male group, the survival time was 100.5 ± 6.5 days for the vehicle-treated TDP-43-A315T mice, and 117.6 ± 7.3 days for the GQD-administered TDP-43-A315T mice. Consequently, when GQD was administered, the average lifespan was extended by 17.1 days (17.0% improvement). In the female group, the survival time was 193.2 ± 4.5 days for the vehicle-treated TDP-43-A315T mice, and 218.6 ± 8.3 days for the GQD-administered TDP-43-A315T mice. As a result, when GQD was administered, the average lifespan was extended by 25.4 days (13.1% improvement) (Fig. 5).

[0190] Improvements in muscle strength in mice were analyzed by measuring rotarod and grip strength. In the rotarod, the GQD-administered group showed higher performance than the vehicle-administered group at 9, 10, and 11 weeks of age in male mice, and statistically significant results were observed. In addition, in female mice, the GQD-administered group showed higher performance than the vehicle-administered group from 10 weeks of age onward, and statistically significant improvements were observed at the final observation point of 28 weeks of age. In the grip strength test, statistical significance was observed at 11 and 13 weeks of age in male mice, and at 21 and 28 weeks of age in female mice (Fig. 6).

[0191] The number of motor neurons (25 μm or larger) located in the ventral horn of the spinal cord was measured, and 30.0 ± 1.4 motor neurons were observed in normal mice, while 11.0 ± 0.5 motor neurons were observed in vehicle-treated TDP-43-A315T mice, showing a significant decrease. On the other hand, 15.4 ± 1.0 motor neurons were observed in TDP-43-A315T mice administered GQDs (Fig. 7a and Fig. 7b).

[0192] To measure the activation of Glia by GQD administration, astrocyte activity was measured by fluorescent staining using GFAP antibody in spinal cord tissue, and microglia activity was measured by fluorescent staining using Iba1 antibody. In the case of normal mice, GFAP positive cells were rarely observed, but in the case of vehicle-treated TDP-43-A315T mice, an average of 4.0 times stronger fluorescence was observed, indicating a significant increase in astrocyte activation. In the TDP-43-A315T mice administered GQD, activation was approximately 2.5 times higher than in the normal mice. In addition, in the case of normal mice, Iba1 positive cells were hardly observed, but in the case of vehicle-treated TDP-43-A315T mice, strong fluorescence was observed about 5.9 times on average, indicating a significant increase in microglia activation. However, in the TDP-43-A315T mice administered GQD, activation was about 3.5 times higher than in the normal mice. This means that GQD significantly reduces microglia activation in TDP-43-A315T mice (Fig. 7c and 7d). TDP-43 protein aggregates in the spinal cord were observed under a fluorescence microscope. As a result, the number of motor neurons in which TDP-43 protein aggregates were formed increased in TDP-43-A315T mice, but was significantly reduced by GQD (Fig. 8).

[0193]

[0194] Experimental Example 4. Lifespan extension and improved exercise performance by GQD in the TDP-43-WT mouse model.

[0195] A drug administration experiment was conducted on 60-day-old female TDP-43-WT mice by intraperitoneal injection of GQD at a weekly dose of 2 mg / kg. In the female group, disease onset occurred at 77.8 ± 4.2 days in vehicle-treated TDP-43-WT mice (n = 12), whereas disease onset occurred at 88.5 ± 4.9 days in GQD-treated TDP-43-WT mice (n = 10). Consequently, when GQD was administered, disease onset was delayed by an average of 10.7 days (13.8% improvement).

[0196] Analysis of the average survival time of mice in the female group showed that the vehicle-treated TDP-43-WT mice had a survival time of 374.5 ± 15.7 days, while the GQD-administered TDP-43-WT mice had a survival time of 421.9 ± 10.2 days. Consequently, when GQDs were administered, the average lifespan was extended by 47.4 days (12.7% improvement) (Fig. 9a).

[0197] To measure muscle strength improvements in mice after GQD administration, rotarod tests and grip strength were performed weekly. For rotarod tests, the GQD-administered group showed statistically significant improvements compared to the vehicle-administered group from 21 weeks of age through the final observation period of 32 weeks. Grip strength was also statistically significantly improved in the GQD-administered group compared to the vehicle-administered group at 20, 26, and 32 weeks of age (Fig. 9b).

[0198] The number of motor neurons (25 μm or more) located in the ventral horn of the spinal cord was measured, and 39.0 ± 1.4 motor neurons were observed in normal mice, while 20.0 ± 0.8 motor neurons were observed in vehicle-treated TDP-43-WT mice, showing a significant decrease. On the other hand, 27.0 ± 1.1 motor neurons were observed in TDP-43-WT mice administered GQD, indicating that the administration of GQD inhibited the death of motor neurons located in the spinal cord (Fig. 10a and Fig. 10b).

[0199] To measure the activation of Glia by GQD administration, astrocyte activity was measured by fluorescent staining using GFAP antibody in spinal cord tissue, and microglia activity was measured by fluorescent staining using Iba1 antibody. In the case of normal mice, GFAP positive cells were rarely observed, but in the case of vehicle-treated TDP-43-WT mice, astrocyte activation was significantly increased with an average of 2.7 times stronger fluorescence. In the case of TDP-43-WT mice administered GQD, astrocyte activation was observed to be approximately 1.9 times higher than that of normal mice. In addition, in the case of normal mice, Iba1 positive cells were hardly observed, but in the case of vehicle-treated TDP-43-WT mice, strong fluorescence was observed about 2.3 times on average, indicating a significant increase in microglia activation, whereas in the case of TDP-43-WT mice administered GQDs, activation was about 1.5 times compared to normal mice (Fig. 10c and Fig. 10d). TDP-43 protein aggregates in the spinal cord were observed under a fluorescence microscope. As a result, the number of motor neurons in which TDP-43 protein aggregates were formed increased in TDP-43-WT mice, but was significantly reduced by GQDs (Fig. 11).

[0200]

[0201] Experimental Example 5. Inhibition of intracellular aggregate formation by GQDs in a FUS cell model.

[0202] It was also confirmed that the death of motor neurons (NSC34 cell line) caused by overexpression of FUS protein or FUS mutant protein was suppressed by GQD (Fig. 12a).

[0203] Additionally, the formation of protein aggregates of G3BP1 (also referred to as G3BP) and FUS proteins was measured by treating HeLa cells with 0.4 M sorbitol, and it was confirmed that the formation of FUS protein aggregates was controlled by GQDs (Figs. 12b and 12c).

[0204] In addition, when FUS mutant proteins were overexpressed and 0.4 M sorbitol was administered, it was confirmed that the FUS mutant proteins formed stress granules with G3BP1 (also referred to as G3BP), which was inhibited by GQD (Fig. 12d).

[0205]

[0206] Experimental Example 6. Inhibition of intracellular aggregate formation by GQDs, extension of lifespan, and improvement of exercise performance in the C9orf72 mouse model.

[0207] The efficacy was evaluated by administering GQD intraperitoneally at a weekly dose of 2 mg / kg at 13 months of age to female C9orf72 mice in which an ALS phenotype was observed.

[0208] In the muscle strength evaluation using grip strength, the results were statistically significantly improved in the GQD administration group 2 months after drug administration (15-month-old and 16-month-old C9orf72 mice) (Fig. 13a).

[0209] The number of motor neurons (25 μm or more) located in the ventral horn of the spinal cord was measured. 27.7 ± 2.4 motor neurons were observed in 16-month-old normal mice, but 12.8 ± 0.9 motor neurons were observed in vehicle-treated C9orf72 mice, showing a significant decrease. On the other hand, 19.3 ± 1.4 motor neurons were observed in C9orf72 mice administered GQD, indicating that the administration of GQD inhibited the death of motor neurons in the spinal cord (Fig. 13b and Fig. 13c).

[0210] To measure the activation of glia by GQD administration, astrocyte activity was measured by fluorescent staining using GFAP antibody in spinal cord tissue, and microglia activity was measured by fluorescent staining using Iba1 antibody. In the case of vehicle-treated C9orf72 mice, astrocyte activation was significantly increased with an average of 2.5 times stronger fluorescence, whereas in the case of GQD-administered C9orf72 mice, astrocyte activation was significantly increased with an average of 1.6 times stronger than in the normal mice. In addition, in the case of normal mice, Iba1 positive cells were rarely observed, whereas in the case of vehicle-treated C9orf72 mice, astrocyte activation was significantly increased with an average of 3.0 times stronger fluorescence, whereas in the case of GQD-administered C9orf72 mice, astrocyte activation was significantly increased with an average of 1.8 times stronger than in the normal mice. This suggests that GQDs significantly reduce the activation of microglia in C9orf72 mice (Fig. 13d and Fig. 13e).

[0211] Furthermore, we observed poly-GR (Fig. 14a) and TDP-43 protein aggregates (Fig. 14b) in the spinal cord caused by the C9orf72 mutation using a fluorescence microscope. As a result, the number of motor neurons in which TDP-43 and poly-GR protein aggregates were formed increased in C9orf72 mice, but this was statistically significantly reduced by GQD.

[0212]

[0213] The foregoing description of the present invention is provided for illustrative purposes only. Those skilled in the art will readily appreciate that the present invention can be readily modified into other specific forms without altering the technical spirit or essential characteristics of the present invention. Therefore, the embodiments described above should be understood as illustrative in all respects and not restrictive.

[0214]

[0215] The present invention includes the effect of utilizing graphene quantum dots as a treatment for a neurodegenerative disease, preferably as a treatment for a TDP-43 protein disease, and more preferably as a treatment for amyotrophic lateral sclerosis or frontotemporal dementia. Graphene quantum dots are expected to exert the effect of delaying the onset of the disease, extending lifespan, improving muscle strength, and preventing persistent nerve damage caused by excessive immune response by controlling the formation of stress granules or protein aggregates, which are the main pathogenesis of the disease, and thus have industrial applicability.

Claims

1. A pharmaceutical composition for preventing or treating a degenerative neurological disease, comprising graphene quantum dots as an active ingredient.

2. In paragraph 1, A pharmaceutical composition for preventing or treating a degenerative neurological disease, wherein the graphene quantum dots have an average diameter of 1 to 100 nm.

3. In paragraph 1, A pharmaceutical composition for preventing or treating a neurodegenerative disease, wherein the neurodegenerative disease is at least one TDP-43 protein disease among amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

4. In paragraph 1, A pharmaceutical composition for preventing or treating a neurodegenerative disease, wherein the graphene quantum dot inhibits one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates.

5. A pharmaceutical composition for preventing or treating a neurodegenerative disease comprising graphene quantum dots as an active ingredient; and A kit comprising instructions for use of a pharmaceutical composition for the prevention or treatment of the above-mentioned degenerative neurological disease.

6. In paragraph 5, A kit wherein the above graphene quantum dots have an average diameter of 1 to 100 nm.

7. In paragraph 5, The above-mentioned neurodegenerative disease is a TDP-43 protein disease of one or more of amyotrophic lateral sclerosis (ALS) or frontotemporal dementia (FTD).

8. In paragraph 5, A kit wherein the above graphene quantum dots inhibit one or more proteins selected from the group consisting of TDP-43, TDP-43-A315T, TDP-43-Q331K, TDP-43 C-terminal fragment-35, TDP-43 C-terminal fragment-25, TDP-43 C-terminal fragment-23, and TDP-43 C-terminal fragment-16 from forming stress granules or protein aggregates.

9. A method for preventing or treating a degenerative neurological disease, comprising administering a composition containing graphene quantum dots as an active ingredient to a subject in need thereof.

10. Use of a composition containing graphene quantum dots as an active ingredient for preventing or treating neurodegenerative diseases.

11. Use of a composition comprising graphene quantum dots as an active ingredient for producing a preparation for preventing or treating a neurodegenerative disease.

Citation Information

Patent Citations

  • Carbon-based quantum dots for regulating amyloid protein as well as preparation method and application of carbon-based quantum dots

    CN110002428A

  • Pharmaceutical composition based on graphene nanostructure for preventing or treating neurodegenerative diseases

    KR1020150115671A

  • A Prestress Cantilever and Expanded Structure Having the Same

    KR102157889B1